-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Buparlisib Hydrochloride in Mantle Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Buparlisib Hydrochloride in Mantle Cell Lymphoma Drug Details: Buparlisib hydrochloride (BKM-120) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Buparlisib Hydrochloride in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Buparlisib Hydrochloride in Refractory Acute Myeloid Leukemia Drug Details: Buparlisib hydrochloride (BKM-120) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Buparlisib Hydrochloride in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Buparlisib Hydrochloride in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Buparlisib Hydrochloride in Solid Tumor Drug Details: Buparlisib hydrochloride (BKM-120) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Buparlisib Hydrochloride in Thymoma (Thymic Epithelial Tumor)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Buparlisib Hydrochloride in Thymoma (Thymic Epithelial Tumor) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Buparlisib Hydrochloride in Thymoma (Thymic Epithelial Tumor) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – buparlisib hydrochloride
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry buparlisib hydrochloride Drug Details Buparlisib hydrochloride (BKM-120) is under development for the treatment of...
-
Sector Analysis
Indonesia Copper Mining Market Analysis including Reserves, Production, Production Forecasts, Operating, Developing and Exploration Assets, Key Players and the Fiscal Regime including Taxes and Royalties, 2019-2024
GlobalData's "Indonesia Copper Mining to 2024 - Updated with Impact of COVID-19" provides a comprehensive coverage on the Indonesian copper mining industry. It provides historical and forecast data on copper production and consumption, major exporters, reserves by country, and world copper prices. The report also includes a demand drivers section providing information on factors that are affecting the country’s copper industry such as demand from Japan, Chinese construction and EV market. It further profiles major copper producers, information on the...
-
Sector Analysis
PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2025
Human epidermal growth factor receptor type 2 (HER2-) breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer can be subdivided into hormone receptor-positive (HER2-/HR+), and triple negative breast cancer (TNBC). The prognoses of HER2-/HR+ and TNBC differ dramatically, as patients with TNBC progress more rapidly towards metastatic disease and only respond to chemotherapy agents. A large number of pipeline agents are being developed in HER2-/HR+ and/or TNBC,...